Back
Anaplastic astrocytoma in adults.
Journal article

Anaplastic astrocytoma in adults.

  • 2007-05-05
Published in:
  • Critical reviews in oncology/hematology. - 2007
Adolescent
Adult
Aged
Antineoplastic Agents, Alkylating
Astrocytoma
Brain Neoplasms
Clinical Trials as Topic
Clinical Trials, Phase II as Topic
Dacarbazine
Female
Humans
Incidence
Male
Middle Aged
Neoplasm Recurrence, Local
Prognosis
Risk Factors
Survival Analysis
Temozolomide
English Anaplastic astrocytoma is an uncommon disease in the adult population. Prognosis is influenced by age, symptom duration, mental status and Karnofsky performance status. A truly complete resection, which is a recognized independent prognostic factor, is not possible and recurrence in the surgical cavity is common. Based on randomized data available, chemotherapy has consistently failed to improve the outcome of patients with anaplastic astrocytoma, while a meta-analysis showed a small, but significant improvement in survival favouring the use of chemotherapy. Outside a clinical trial, postoperative radiotherapy (30 x 2 Gy) remains the standard adjuvant therapy for most patients. For elderly patients, the application of treatment is usually based on performance status and neurological function. In recurrent disease, chemotherapy with temozolomide has been proven to be active and well-tolerated in phase II trials, but no comparative phase III trials of other cytotoxic drugs have been conducted.
Language
  • English
Open access status
closed
Identifiers
Persistent URL
https://sonar.ch/global/documents/19947
Statistics
Document views: 16 File downloads: